FDA Adverse Event Injury Summary report: N

BD BACTEC¿ PEDS PLUS¿/ F CULTURE VIALS (PLASTIC)

MDR report key: 21113843 · Received January 9, 2025

Report

Report Number
2647876-2025-00001
Event Type
Injury
Date Received
January 9, 2025
Date of Event
December 10, 2024
Report Date
March 28, 2025
Manufacturer
BECTON DICKINSON CARIBE LTD.
Product Code
MDB
UDI-DI
00382904420208
PMA / PMN Number
K151866
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
PA, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

E.1: INITIAL REPORTER ADDR 1: (B)(6). THE INFORMATION FOR THE ADDITIONAL 510K IS AS FOLLOWS: G4. PMA / 510(K)#: K173873 A DEVICE EVALUATION AND/OR DEVICE HISTORY REVIEW IS ANTICIPATED BUT IS NOT COMPLETE. UPON COMPLETION, A SUPPLEMENTAL REPORT WILL BE FILED.

Additional Manufacturer Narrative · 0

AFTER FURTHER EVALUATION OF THE COMPLAINT, IT HAS BEEN DETERMINED THAT THE PREVIOUSLY SUBMITTED REPORT 2647876-2025-00001 WAS SENT IN ERROR. THERE WAS NO REPORT OF SERIOUS INJURY, MEDICAL INTERVENTION, OR REPORTABLE DEVICE MALFUNCTION. THEREFORE, THIS IS NOT CONSIDERED TO BE A REPORTABLE MALFUNCTION.

Additional Manufacturer Narrative · 0

INVESTIGATION SUMMARY - CATALOG 442020. BATCH NO. 4136597. CUSTOMER REPORTED A FALSE POSITIVE DEFECT. NEITHER PHOTOS NOR RETURNED GOOD SAMPLES WERE RECEIVED. BD WAS UNABLE TO REPRODUCE CUSTOMER EXPERIENCE WITH THE BACTEC PRODUCT. A FALSE POSITIVE RESPONSE WAS NOT OBSERVED WHEN RETENTION SAMPLES WERE TESTED. BATCH HISTORY RECORDS WERE REVIEWED, AND ALL TESTING WERE WITHIN SPECIFICATION FOR PRODUCT RELEASE. A COMPLAINT HISTORY REVIEW WAS CONDUCTED AND ONLY THE CURRENT COMPLAINT WAS FOUND RELATING TO THE INCIDENT LOT NUMBER AND THE ¿AS REPORTED¿ DEFECT CODE. THERE IS NO FALSE POSITIVE ROOT CAUSE ASSOCIATED WITH PLOTS RECEIVED. COMPLAINT IS UNCONFIRMED BASED ON RETENTION SAMPLES AND BATCH HISTORY RECORD REVIEW RESULTS. NO CORRECTIVES ACTIONS WERE REQUIRED. A CROSS FUNCTIONAL TEAM CONTINUALLY MONITORS ALL PRODUCT COMPLAINTS FOR TRENDS AND DETERMINES IF ANY ADDITIONAL ACTIONS ARE NECESSARY BEYOND THE CURRENT INVESTIGATION PROCESS.

Description of Event or Problem · 0

IT WAS REPORTED WHILE USING BD BACTEC¿ PEDS PLUS¿/ F CULTURE VIALS (PLASTIC) THERE WAS ONE FALSE POSITIVE PATIENT RESULT. THE PATIENT WAS INITIALLY BEING TREATED WITH CEFEPIME AND VANCOMYCIN. HOWEVER, BASED ON THE RESULTS, VANCOMYCIN WAS DISCONTINUED, AND CEFEPIME COVERAGE WAS EXTENDED. AFTER THE CORRECTED RESULTS WERE RECEIVED, CEFEPIME WAS ALSO DISCONTINUED. NO ADVERSE IMPACT WAS REPORTED AS A RESULT OF THE TREATMENT CHANGE.

Description of Event or Problem · 0

IT WAS REPORTED WHILE USING BD BACTEC¿ PEDS PLUS¿/ F CULTURE VIALS (PLASTIC) THERE WAS ONE FALSE POSITIVE PATIENT RESULT. THE PATIENT WAS INITIALLY BEING TREATED WITH CEFEPIME AND VANCOMYCIN. HOWEVER, BASED ON THE RESULTS, VANCOMYCIN WAS DISCONTINUED, AND CEFEPIME COVERAGE WAS EXTENDED. AFTER THE CORRECTED RESULTS WERE RECEIVED, CEFEPIME WAS ALSO DISCONTINUED. NO ADVERSE IMPACT WAS REPORTED AS A RESULT OF THE TREATMENT CHANGE.

Description of Event or Problem · 0

IT WAS REPORTED WHILE USING BD BACTEC¿ PEDS PLUS¿/ F CULTURE VIALS (PLASTIC) THERE WAS ONE FALSE POSITIVE PATIENT RESULT. THE PATIENT WAS INITIALLY BEING TREATED WITH CEFEPIME AND VANCOMYCIN. HOWEVER, BASED ON THE RESULTS, VANCOMYCIN WAS DISCONTINUED, AND CEFEPIME COVERAGE WAS EXTENDED. AFTER THE CORRECTED RESULTS WERE RECEIVED, CEFEPIME WAS ALSO DISCONTINUED. NO ADVERSE IMPACT WAS REPORTED AS A RESULT OF THE TREATMENT CHANGE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1169422 BD BACTEC¿ PEDS PLUS¿/ F CULTURE VIALS (PLASTIC) SYSTEM, BLOOD CULTURING MDB BECTON DICKINSON CARIBE LTD. 4136597 00382904420208

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Other